Latest filing published 19 Dec 2012 for ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/, €93.
Insider track record
No signal scores available.
Closed purchases
Based on 16 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +50.0%Entry US$2.54 · Close at T+365 US$3.81
- +42.0%Entry US$2.45 · Close at T+365 US$3.48
- -28.4%Entry US$3.80 · Close at T+365 US$2.72
- -18.5%Entry US$3.25 · Close at T+365 US$2.65
- -34.7%Entry US$3.66 · Close at T+365 US$2.39
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Michael S. Gunter: trading record in brief
Michael S. Gunter is a declared insider at 2 companies; the most frequent names are Arrhythmia Research Technology Inc /DE/ and Primo Water Corp. Between 10 November 2010 and 18 December 2012, the trades on record add up to 29 filings.
The open-market side counts 24 purchases for €44k alongside 1 sale for €57k. Sales outweigh purchases by €13k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant. In 2012 alone, the filings show 16 purchases and no sales.
In size, the median ticket on the buying side is €1,054. For 16 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 69% of cases, with a median move of +3.7%. This is a record of the past, not a forecast.
On 19 December 2012 came the latest disclosure, an open-market purchase for €93 in Arrhythmia Research Technology Inc /DE/. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Michael S. Gunter
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 46 shares@ US$2.65Common StockSEC:0000819689-12-000079:0Canonical exit: 17 Mar 2013 (T+90)
- 1,625 shares@ US$2.65Common StockSEC:0000819689-12-000079:1Canonical exit: 17 Mar 2013 (T+90)
- 3,329 shares@ US$2.60Common StockSEC:0000819689-12-000079:2Canonical exit: 18 Mar 2013 (T+90)
- 600 shares@ US$2.40Common StockSEC:0000819689-12-000078:0Canonical exit: 5 Mar 2013 (T+90)
- 300 shares@ US$2.59Common StockSEC:0000819689-12-000078:1Canonical exit: 6 Mar 2013 (T+90)
- 4,000 shares@ US$2.60Common StockSEC:0000819689-12-000078:2Canonical exit: 6 Mar 2013 (T+90)
- 100 shares@ US$2.39Common StockSEC:0000819689-12-000077:0Canonical exit: 3 Mar 2013 (T+90)
- 300 shares@ US$4.85Common StockSEC:0001504240-12-000001:0Canonical exit: 11 Sept 2011 (T+90)
- 500 shares@ US$3.20Common StockSEC:0001504240-11-000004:0Canonical exit: 12 Mar 2012 (T+90)
- 2,000 shares@ US$3.40Common StockSEC:0001504240-11-000003:0Canonical exit: 27 Feb 2012 (T+90)
- 100 shares@ US$3.38Common StockSEC:0001504240-11-000003:1Canonical exit: 27 Feb 2012 (T+90)
- 200 shares@ US$3.39Common StockSEC:0001504240-11-000003:2Canonical exit: 27 Feb 2012 (T+90)
- 600 shares@ US$3.55Common StockSEC:0001504240-11-000002:0Canonical exit: 13 Dec 2011 (T+90)
- 100 shares@ US$3.55Common StockSEC:0001504240-11-000002:1Canonical exit: 13 Dec 2011 (T+90)
- 100 shares@ US$3.60Common StockSEC:0001504240-11-000002:2Canonical exit: 13 Dec 2011 (T+90)
- 900 shares@ US$3.60Common StockSEC:0001504240-11-000002:3Canonical exit: 13 Dec 2011 (T+90)
- 7,255 shares@ US$11.26Common StockSEC:0001181431-11-037944:0
- 10,000 shares0Common StockSEC:0001181431-11-020811:0
- 1,916 sharesCommon StockSEC:0001181431-10-055559:0
- 547 sharesCommon StockSEC:0001181431-10-055559:1
- 11,820 sharesSeries B Preferred StockSEC:0001181431-10-055559:2
21 of 21 declarations
